Description

CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. Dose adjustments may be recommended CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. Dose adjustments may be recommended Gastric Acid Reducing Agents: Avoid co-administration with proton pump

Based on findings in animals, Acalabrutinib may cause fetal harm and dystocia when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. No data are available regarding the presence of Acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production.

Serious and Opportunistic Infections: Monitor for signs and symptoms of infection and treat promptly Hemorrhage: Monitor for bleeding and manage appropriately Cytopenias: Monitor complete blood counts regularly Second Primary Malignancies: Other malignancies have occurred, including skin cancers and other solid tumors. Advise patients to use sun protection Atrial Fibrillation and Flutter: Monitor for symptoms of arrhythmias and manage

Tyrosine Kinase Inhibitor

Do not store above 30⁰C. Keep away from light and out of the reach of children.